Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
MWN-109 in Weight Loss: NCT07804797 Clinical Landscape Report 2026
16 September 2026
NCT07804797 clinical landscape for Weight Loss: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Acetaminophen in Diabetes Mellitus, Type 1: NCT07803744 Clinical Landscape Report 2026
16 September 2026
NCT07803744 clinical landscape for Diabetes Mellitus, Type 1: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MT-1 in Obesity: NCT07805291 Clinical Landscape Report 2026
16 September 2026
NCT07805291 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in pMMR/MSS/MSI-L Colon Cancer: NCT07808151 Clinical Landscape Report 2026
16 September 2026
NCT07808151 clinical landscape for pMMR/MSS/MSI-L Colon Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
8 min read
Gut-X-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Gut-X-001: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
XmAb-942 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
XmAb-942: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
nL-ATN1-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
nL-ATN1-001: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
MDX-2003 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
MDX-2003: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
BMN-331 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
BMN-331: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Bacteriophage Therapy(National Institute of Allergy and Infectious Diseases) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
Bacteriophage Therapy(National Institute of Allergy and Infectious Diseases): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
nL-TUBB4-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
nL-TUBB4-001: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position.
8 min read
DB-1419 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 September 2026
DB-1419: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.